Pancreatic Ductal Adenocarcinoma Pdac clinical trials

Explore recruiting pancreatic ductal adenocarcinoma pdac clinical trials.

Recruiting pancreatic ductal adenocarcinoma pdac studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Ductal Adenocarcinoma Pdac trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Examining the impact of propranolol on preoperative anxiety and on tumorigenic changes in patients with pancreatic ductal adenocarcinomas: a randomized, triple-blinded, placebo-controlled pilot trial (The IMPULS trial)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

France, Spain, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/randomized Phase II, open-label multicenter trial to evaluate the safety, tolerability, and efficacy of mFOLFIRINOX with or without BNT321 as adjuvant therapy following curative resection in patients with pancreatic adenocarcinoma

Denmark, Spain, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Portugal, Spain, France, Italy, Germany, Austria

Phase II and Phase III (Integrated) EU CTIS Study details

Pancreatic Ductal Adenocarcinoma Pdac trials by city

Pancreatic Ductal Adenocarcinoma Pdac in Toronto Pancreatic Ductal Adenocarcinoma Pdac in Vancouver Pancreatic Ductal Adenocarcinoma Pdac in Montreal Pancreatic Ductal Adenocarcinoma Pdac in Calgary Pancreatic Ductal Adenocarcinoma Pdac in Edmonton Pancreatic Ductal Adenocarcinoma Pdac in Ottawa Pancreatic Ductal Adenocarcinoma Pdac in Winnipeg Pancreatic Ductal Adenocarcinoma Pdac in Quebec City Pancreatic Ductal Adenocarcinoma Pdac in Hamilton Pancreatic Ductal Adenocarcinoma Pdac in Kitchener Pancreatic Ductal Adenocarcinoma Pdac in London Pancreatic Ductal Adenocarcinoma Pdac in Halifax Pancreatic Ductal Adenocarcinoma Pdac in New York Pancreatic Ductal Adenocarcinoma Pdac in Los Angeles Pancreatic Ductal Adenocarcinoma Pdac in Chicago Pancreatic Ductal Adenocarcinoma Pdac in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease